165 related articles for article (PubMed ID: 20599429)
1. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.
Johnson TA; Shames I; Keezer M; Lapierre Y; Haegert DG; Bar-Or A; Antel J
Clin Immunol; 2010 Oct; 137(1):15-20. PubMed ID: 20599429
[TBL] [Abstract][Full Text] [Related]
2. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
Morris MA; Gibb DR; Picard F; Brinkmann V; Straume M; Ley K
Eur J Immunol; 2005 Dec; 35(12):3570-80. PubMed ID: 16285007
[TBL] [Abstract][Full Text] [Related]
3. [Fingolimod treatment in multiple sclerosis].
Tanaka M
Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
[TBL] [Abstract][Full Text] [Related]
4. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
5. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
6. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.
Francis G; Kappos L; O'Connor P; Collins W; Tang D; Mercier F; Cohen JA
Mult Scler; 2014 Apr; 20(4):471-80. PubMed ID: 23950550
[TBL] [Abstract][Full Text] [Related]
7. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
Johnson TA; Lapierre Y; Bar-Or A; Antel JP
Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
[TBL] [Abstract][Full Text] [Related]
8. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S; von Andrian UH
N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
[No Abstract] [Full Text] [Related]
10. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
Henault D; Galleguillos L; Moore C; Johnson T; Bar-Or A; Antel J
Neurology; 2013 Nov; 81(20):1768-72. PubMed ID: 24132373
[TBL] [Abstract][Full Text] [Related]
11. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.
Warnke C; Dehmel T; Ramanujam R; Holmen C; Nordin N; Wolfram K; Leussink VI; Hartung HP; Olsson T; Kieseier BC
Neurology; 2014 Dec; 83(23):2153-7. PubMed ID: 25361781
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets of FTY720 (fingolimod).
Pitman MR; Woodcock JM; Lopez AF; Pitson SM
Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
[TBL] [Abstract][Full Text] [Related]
13. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
[TBL] [Abstract][Full Text] [Related]
15. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
Hofmann M; Brinkmann V; Zerwes HG
Int Immunopharmacol; 2006 Dec; 6(13-14):1902-10. PubMed ID: 17161343
[TBL] [Abstract][Full Text] [Related]
16. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP
J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858
[TBL] [Abstract][Full Text] [Related]
17. [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
Klatt J; Hartung HP; Hohlfeld R
Nervenarzt; 2007 Oct; 78(10):1200-8. PubMed ID: 17668161
[TBL] [Abstract][Full Text] [Related]
18. The effect of a novel immunosuppressant, FTY720, in mice without secondary lymphoid organs.
Sugito K; Koshinaga T; Inoue M; Ikeda T; Hagiwara N; Fukuzawa M
Surg Today; 2005; 35(8):662-7. PubMed ID: 16034547
[TBL] [Abstract][Full Text] [Related]
19. Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Fujiwara M; Anstadt EJ; Khanna KM; Clark RB
Clin Immunol; 2015 May; 158(1):103-13. PubMed ID: 25829233
[TBL] [Abstract][Full Text] [Related]
20. Blocking lymphocyte trafficking with FTY720 prevents inflammation-sensitized hypoxic-ischemic brain injury in newborns.
Yang D; Sun YY; Bhaumik SK; Li Y; Baumann JM; Lin X; Zhang Y; Lin SH; Dunn RS; Liu CY; Shie FS; Lee YH; Wills-Karp M; Chougnet CA; Kallapur SG; Lewkowich IP; Lindquist DM; Murali-Krishna K; Kuan CY
J Neurosci; 2014 Dec; 34(49):16467-81. PubMed ID: 25471584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
